Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1651 to 1665 of 8933 results

  1. Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)

    Evidence-based recommendations on nivolumab (Opdivo) as a possible treatment for completely resected oesophageal or gastro-oesophageal junction cancer in adults.

    Technology appraisal guidance
    Published
    17 November 2021
    View recommendations

    Sections for TA746

  2. Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) (TA923)

    NICE is unable to make a recommendation on tabelecleucel (Ebvallo) for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus. This is because Pierre Fabre Ltd did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    19 October 2023

    Sections for TA923

  3. Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)

    Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

    Technology appraisal guidance
    Published
    17 October 2023
    View recommendations

    Sections for TA927

  4. Dapsone for treating COVID-19 in people 40 years and over with high-risk comorbidity and people 70 years and over [TSID11892]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Subcutaneous C1-esterase inhibitor for preventing recurrent attacks of hereditary angioedema in people 12 years and over [TSID11891]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Avtozma (tocilizumab biosimilar) for treating moderate to severe rheumatoid arthritis in people aged 18 to 75 [TSID11848]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome [TSID11820]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. CT-P39 (omalizumab biosimilar) for previously treated chronic spontaneous urticaria [TSID11832]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Semaglutide for treating obesity-related heart failure with preserved ejection fraction [TSID11788]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Subcutaneous efgartigmod for treating generalised myasthenia gravis [TSID11835]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. NPJ5008 for treating malignant hyperthermia [TSID11829]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TSID10639]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 [TSID11828]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Bardoxolone methyl for treating chronic kidney disease in people 12 years and over with Alport syndrome [TSID9998]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation